ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:47:10 2024-05-20 EDT			5-day change	1st Jan Change
0.0157 ^USD	+5.85%		+4.67%	-17.37%

05-15	ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-29	ProtoKinetix, Incorporated announced a financing transaction	CI

Protokinetix, Incorporated Reports Earnings Results for the Second Quarter Ended June 30, 2020

July 10, 2020 at 01:40 pm

ProtoKinetix, Incorporated announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced net loss was USD 2.205 million compared to USD 769,249 a year ago. Basic loss per share from continuing operations was USD 0.01. For the half year, net loss was USD 5.375 million compared to USD 1.151 million a year ago. Basic loss per share from continuing operations was USD 0.01.

Latest news about ProtoKinetix, Incorporated

ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
ProtoKinetix, Incorporated announced a financing transaction	03-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.11 million in funding	12-25	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
ProtoKinetix, Incorporated announced that it has received $0.03 million in funding	23-08-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	23-03-16	CI
ProtoKinetix, Incorporated announced that it has received $0.04 million in funding	23-01-22	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.037 million in funding	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.063 million in funding	22-12-08	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-07	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
ProtoKinetix, Incorporated announced that it has received funding	22-10-13	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	22-07-20	CI
ProtoKinetix, Incorporated announced a financing transaction	22-07-10	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.2 million in funding	22-07-10	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
ProtoKinetix, Incorporated announced that it has received $0.05 million in funding	22-03-17	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI

Chart ProtoKinetix, Incorporated

Duration

Period

More charts

Company Profile

ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTOKINETIX, INCORPORATED	-17.37%	5.24M
MODERNA, INC.	+39.06%	50.93B
IQVIA HOLDINGS INC.	-0.21%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.98%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-22.44%	18.9B
BIO-TECHNE CORPORATION	+8.26%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.54%	12.17B
MEDPACE HOLDINGS, INC.	+29.91%	12.16B

Other Biotechnology & Medical Research